Medtronic is advancing the separation of its diabetes business, stating that it plans to raise as much as $784 million through an initial public offering of its MiniMed division.
Following the offering, the newly public company intends to list on the Nasdaq under the ticker symbol “MMED.” At the top end of the proposed price range, the transaction would imply a valuation of up to $7.86 billion.
Headquartered in Northridge, California, the MiniMed unit employs more than 8,000 people. The division manufactures insulin pumps, glucose monitoring systems, sensors, and smart insulin pen hardware. Among its products is the MiniMed 780G insulin pump, and the business has also introduced sensor improvements in recent quarters.
Last year, Medtronic announced its intention to separate the $2.8 billion diabetes business through an IPO followed by a subsequent split-off. The diabetes division represents Medtronic’s smallest segment by revenue. The company said the separation is part of a broader effort to simplify its portfolio and sharpen its focus on higher-margin growth markets.
The planned carve-out follows other structural changes undertaken in recent years. In 2023, Medtronic created Mozarc Medical, a kidney-care-focused joint venture with DaVita. In 2024, the company exited the ventilator business as part of its efforts to streamline operations.
Medtronic originally acquired MiniMed nearly 25 years ago in a transaction valued at close to $3.3 billion. In the past few years, the diabetes unit has faced regulatory concerns related to quality management and cybersecurity issues affecting certain devices. Despite those challenges, the business has returned to growth in recent quarters, supported by its 780G insulin pump and sensor updates.
IPOX Research Associate Lukas Muehlbauer said the company brings an established operating history to the public markets. “With over 40 years of insulin pump manufacturing, MiniMed enters the market as an established business rather than a startup. The separation allows the company to target investors seeking pure-play exposure to diabetes technology,” Muehlbauer said.
He also stated that although the company has demonstrated strong revenue growth, operating as a standalone entity would mean losing Medtronic’s financial backing. Muehlbauer noted that MiniMed has posted net losses for three consecutive years and that investors will expect a clearly defined path toward profitability.
The IPO is being led by Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley, which are acting as active bookrunners on the transaction. Medtronic has indicated that it expects to complete a split-off of MiniMed approximately six months after the IPO is finalized.
The proposed listing represents a further step in Medtronic’s plan to separate its diabetes operations into an independent publicly traded company.
Medtronic Advances MiniMed IPO Strategy
Medtronic is seeking to raise up to $784 million through the initial public offering of its diabetes business, MiniMed.
The planned public listing of the diabetes unit represents a significant shift in corporate structure and capital strategy. By carving out the business into a separately traded entity, leadership aims to improve transparency around financial performance and operational priorities. Investors will gain clearer insight into revenue growth, margins, and product pipeline developments within the diabetes segment.
The diabetes technology market remains highly competitive, with demand rising due to increasing global prevalence of both type 1 and type 2 diabetes. Advanced insulin delivery systems, smart insulin pens, and integrated continuous glucose monitoring platforms are driving innovation. A standalone structure could allow the newly listed company to accelerate partnerships, product launches, and digital health integrations without being weighed down by broader corporate objectives.
Growth Drivers in the Diabetes Technology Market
Several key factors are fueling expansion in this sector:
-
Rising global diabetes diagnoses
-
Growing adoption of automated insulin delivery systems
-
Increasing reimbursement coverage for advanced devices
-
Integration of AI-driven analytics into glucose monitoring platforms
A focused corporate framework may help the diabetes unit respond more rapidly to these trends, particularly as competitors continue investing in next-generation closed-loop systems.
